Livestock Therapeutics & Vaccines Market Size & Share 2026-2035

 Livestock Therapeutics & Vaccines Market Size   

The global livestock therapeutics & vaccines market was valued at USD 18.2 billion in 2025. The market is expected to grow from USD 19.4 billion in 2026 to USD 31.5 billion in 2035, at a CAGR of 5.6% during the forecast period, according to the latest report published by Global Market Insights Inc.

The rising prevalence of infectious diseases, parasitic infestations, and production-related disorders in livestock is a major driver of the livestock therapeutics & vaccines market. According to the World Organisation for Animal Health, around 20% of global animal production is lost annually due to animal diseases, highlighting the significant economic burden on the livestock industry. Additionally, the Food and Agriculture Organization projects that global food production will need to increase by approximately 70% by 2050 to meet the demands of a growing population, placing greater emphasis on maintaining healthy and productive livestock populations. Growing global demand for meat, milk, and eggs, coupled with increasing herd sizes and intensified commercial farming, has accelerated the need for effective vaccines, anti-infectives, antiparasitics, and anti-inflammatory therapeutics.

Continuous innovation in livestock therapeutics and vaccine technologies is significantly transforming the market landscape. Advances in recombinant and vector-based vaccines, mRNA vaccine research, precision veterinary medicine, and rapid diagnostic technologies are enabling earlier disease detection and more targeted treatment strategies. In addition, long-acting injectable formulations, combination vaccines, improved adjuvant systems, and sustained-release antiparasitics products are enhancing treatment compliance while reducing handling stress in animals. The integration of digital livestock health monitoring, precision farming technologies, and genomics-based breeding programs is further improving disease surveillance and preventive healthcare. Ongoing investments in next-generation biologics, antimicrobial alternatives, and novel vaccine platforms are expected to strengthen market growth throughout the forecast period.

The livestock therapeutics & vaccines market is highly competitive, with leading companies such as Zoetis, Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, and Ceva Santé Animale, among others. These companies maintain their competitive position through diversified portfolios of vaccines, parasiticides, anti-infectives, and reproductive health products, alongside continuous investments in biological innovation. Market participants are actively expanding their vaccine pipelines targeting swine, poultry, cattle, sheep, and aquaculture diseases while strengthening manufacturing capacity and global distribution networks. Furthermore, strategic collaborations, acquisitions, licensing agreements, and investments in biotechnology are enhancing product development capabilities and expanding access to advanced livestock healthcare solutions across both developed and emerging markets.

The livestock therapeutics & vaccines market expanded as livestock producers increasingly prioritized disease prevention to minimize production losses and improve food security. Growth was supported by expanding commercial livestock production, rising veterinary healthcare expenditure, government-led animal disease control and vaccination programs, and increasing awareness regarding antimicrobial stewardship. In addition, regulatory support for preventive vaccination, greater adoption of companion diagnostics in animal health, and continued investments in veterinary pharmaceutical research have accelerated the commercialization of innovative livestock health products.

The livestock therapeutics & vaccines industry encompasses pharmaceutical products and biological solutions developed to prevent, control, and treat diseases affecting food-producing animals. It includes vaccines, anti-infectives, antiparasitics, anti-inflammatory drugs, metabolic disorder treatments, and other veterinary medicines used across cattle, swine, poultry, sheep, goats, aquaculture species, and other livestock. These products are extensively utilized to improve animal health, enhance productivity, reduce mortality, strengthen biosecurity, and support sustainable livestock production while ensuring food safety and animal welfare.   

Livestock Therapeutics & Vaccines Market Trends

The livestock therapeutics & vaccines industry is being driven by the increasing prevalence of infectious and parasitic diseases in food-producing animals worldwide. The market is also supported by advances in veterinary biologics, stronger disease surveillance programs, and growing investments in preventive animal healthcare.

• The livestock sector continues to play a vital role in global agriculture. According to the Food and Agriculture Organization, livestock contributes approximately 40% of the global agricultural GDP, emphasizing the importance of maintaining animal health through effective therapeutics and vaccination programs.
• The growing cattle population is supporting demand for livestock healthcare products. According to the Food and Agriculture Organization, the global cattle population exceeds 1.5 billion head, creating sustained demand for vaccines, antiparasitics, reproductive health products, and anti-infective therapeutics.
• Moreover, poultry remains the fastest-growing livestock segment worldwide. According to the latest FAOSTAT data, the global chicken population reached approximately 26.56 billion birds in 2022. The large commercial poultry population continues to drive routine vaccination against diseases such as Newcastle disease, infectious bronchitis, and highly pathogenic avian influenza, thereby supporting demand for poultry vaccines and therapeutics.
• Swine diseases continue to create significant economic challenges for producers. According to the World Organisation for Animal Health, African swine fever has affected more than 50 countries across multiple continents since its global spread, accelerating investments in disease surveillance, biosecurity, and vaccine development.
• The increasing adoption of companion diagnostics, genomic surveillance, recombinant vaccines, vector-based vaccines, and improved adjuvant technologies is enhancing disease prevention while improving vaccine efficacy and duration of immunity across commercial livestock operations.
• Rising concerns regarding antimicrobial resistance are accelerating the transition toward preventive vaccination. According to the World Health Organization, antimicrobial resistance is among the top 10 global public health threats, prompting governments to promote responsible antimicrobial use and increase vaccination coverage in food-producing animals.
• Furthermore, aquaculture is emerging as an important growth area for veterinary biologics. According to the Food and Agriculture Organization, aquaculture now supplies over 50% of aquatic animals produced for human consumption, increasing demand for fish vaccines and aquatic animal therapeutics.
• Continuous investments by governments and private companies in next-generation vaccine platforms, monoclonal antibodies, long-acting injectable formulations, precision livestock farming, and digital animal health monitoring are improving herd health management while reducing disease-related production losses.
• Lastly, expanding veterinary infrastructure, increasing livestock insurance programs, stronger regulatory support for animal disease eradication, and rising awareness regarding preventive herd health management are accelerating the adoption of advanced therapeutics and vaccines across developed and emerging markets, supporting long-term market growth.

Livestock Therapeutics & Vaccines Market Analysis

Based on the product type, the livestock therapeutics & vaccines market is segmented into therapeutics and vaccines. The therapeutics segment dominated the market with USD 11.1 billion in 2025.    

• The therapeutics segment accounted for the largest share of the livestock therapeutics & vaccines industry in 2025, owing to the continuous need for disease treatment and herd health management across commercial livestock production systems. Growing emphasis on improving animal productivity, reducing mortality, and minimizing economic losses has accelerated the adoption of veterinary pharmaceuticals.
• According to the World Health Organization, more than 60% of emerging infectious diseases in humans originate from animals, reinforcing the importance of effective disease management in livestock. Therapeutics such as ivermectin, florfenicol, ceftiofur, meloxicam, and tulathromycin are extensively used to improve animal health, productivity, and welfare.
• Furthermore, increasing veterinary healthcare expenditure, expanding commercial livestock production, and improved veterinary access are expected to sustain demand for livestock therapeutics over the forecast period.
• On the other hand, the vaccine segment was valued at USD 7.1 billion in 2025. The segment is driven by the growing adoption of preventive vaccination programs and increasing use of recombinant, inactivated, and live attenuated vaccines across commercial livestock production.
• Rising immunization against diseases such as Newcastle disease, foot-and-mouth disease, and bovine respiratory disease continues to improve herd immunity, reduce disease outbreaks, and enhance livestock productivity.

Based on the animal type, the livestock therapeutics & vaccines market is divided into poultry, cattle, swine, sheep and goats, aquaculture, and other animal types. The cattle segment accounted for a significant market share of 34.6% in 2025.   

• Cattle require routine vaccination and therapeutic interventions to prevent and treat diseases such as bovine respiratory disease, mastitis, foot-and-mouth disease, and parasitic infections. According to the Food and Agriculture Organization, global milk production reached approximately 944 million tonnes in 2023, reflecting the growing importance of maintaining healthy dairy herds.
• Additionally, the increasing adoption of artificial insemination, reproductive hormone therapies, mineral supplements, and herd health monitoring programs is improving fertility rates, milk yield, and overall herd productivity. The growing commercialization of dairy and beef farming, coupled with expanding government-led disease surveillance and vaccination initiatives, is further accelerating the demand for advanced cattle therapeutics and vaccines.
• Further, increasing investments in reproductive health products, disease prevention programs, and precision livestock management are expected to support sustained demand for cattle therapeutics and vaccines.
• On the other hand, the poultry segment is expected to witness significant growth of 5.7% over the forecast period. Rising global poultry production and increasing vaccination against diseases such as Newcastle disease, highly pathogenic avian influenza, and infectious bronchitis are driving demand for poultry therapeutics and vaccines to improve flock health and production efficiency.  
• Swine segment was valued at USD 3.8 billion in 2025. Swine producers are increasingly prioritizing preventive disease management through routine vaccination programs, which is driving the revenue growth in the segment.

• Diseases such as foot-and-mouth disease, African swine fever, Newcastle disease, and bovine viral diarrhea continue to cause substantial production losses and mortality worldwide. According to the World Organisation for Animal Health, foot-and-mouth disease is endemic in more than 77% of the global livestock population, highlighting the continued need for routine vaccination and surveillance programs.
• Moreover, the frequent occurrence of transboundary disease outbreaks has resulted in stricter animal movement regulations and expanded national immunization campaigns across major livestock-producing countries. Growing investments in next-generation vaccines, rapid molecular diagnostics, and disease surveillance systems are enabling earlier outbreak detection, minimizing production losses, and improving livestock health management.
• Furthermore, increasing government-led disease eradication initiatives, stricter biosecurity regulations, and growing adoption of recombinant and multivalent vaccines are expected to support sustained growth of the viral diseases segment.

• On the other hand, the bacterial diseases segment was valued at USD 4.7 billion in 2025 and is anticipated to witness significant growth throughout the forecast period. Increasing incidence of diseases such as bovine respiratory disease, mastitis, and salmonellosis is driving demand for antibiotics, vaccines, and rapid diagnostics, while antimicrobial stewardship programs are encouraging the development of safer and more targeted therapeutic solutions.
• Parasitic diseases segment was valued at USD 4.2 billion in 2025. Livestock producers are increasingly implementing integrated parasite control strategies that combine antiparasitics therapeutics, herd monitoring, pasture management, and biosecurity measures to improve animal health and production efficiency. These approaches are driving the revenue growth in the segment.

Based on the route of administration, the livestock therapeutics & vaccines market is divided into injectable (parenteral), oral, topical, intranasal/inhalation, and other routes of administration. The injectable (parenteral) segment dominated the market in 2025 and is expected to grow with a significant CAGR of 5.5% over the analysis period.    

• Injectable formulations are extensively used for the administration of antibiotics, antiparasitics, anti-inflammatory drugs, reproductive hormones, nutritional supplements, and vaccines, particularly in cattle, swine, sheep, and goats. They are widely preferred for the treatment of severe bacterial and viral infections, emergency conditions, and herd vaccination programs where immediate therapeutic response is required.
• Common injectable products include ceftiofur, florfenicol, oxytetracycline, ivermectin, meloxicam, and oxytocin, which are routinely used to manage respiratory diseases, mastitis, parasitic infestations, pain, inflammation, and reproductive disorders. Furthermore, long-acting injectable formulations are gaining popularity owing to their ability to improve treatment compliance, reduce handling stress, and minimizing labor costs.
• Continuous advancements in sustained-release formulations, injectable biologics, and veterinary drug delivery technologies are expected to further strengthen the growth of the injectable (parenteral) segment over the forecast period.
• Oral segment was valued at USD 5 billion in 2025. Oral formulations are gaining traction in large-scale livestock operations as they enable treatment or prophylaxis of entire herds/flocks through feed or water systems, reducing labor requirements and handling stress.
• Additionally, Topical segment was valued at USD 1.8 billion in 2025. Topical treatments are extensively being used for the treatment of tick-borne diseases, lice, mites, and fly infestations, continuing to creating significant revenue growth in the segment.

Based on the distribution channel, the livestock therapeutics & vaccines market is segmented into veterinary hospital pharmacies, E-commerce, retail pharmacies, and other distribution channels. The veterinary hospital pharmacies segment dominated the market with USD 8.4 billion in 2025 and is expected to reach USD 14.2 billion by 2035, driven by the increasing number of livestock disease cases requiring professional diagnosis, prescription-based treatment, and supervised administration of veterinary medicines.

• Veterinary hospitals serve as primary distribution channels for a broad range of therapeutics and vaccines. They also play a critical role in disease diagnosis, vaccination programs, surgical procedures, emergency care, and herd health management for cattle, swine, poultry, sheep, and goats. According to the World Organisation for Animal Health, strengthening veterinary services is a key component of improving animal health systems and controlling transboundary animal diseases worldwide.
• Furthermore, the growing adoption of preventive healthcare, increasing government-supported livestock vaccination campaigns, expanding veterinary infrastructure, and rising awareness among livestock producers regarding timely disease diagnosis and treatment are expected to support continued growth of the veterinary hospital pharmacies segment.
• Additionally, improved cold-chain storage facilities and greater availability of advanced biologics and prescription veterinary medicines are further enhancing the role of veterinary hospital pharmacies in livestock healthcare.
• Retail pharmacies segment is expected to show lucrative growth of about 5.9% during the forecast period and is expected to be valued at USD 11.3 billion in 2035.  Retail pharmacies are increasingly expanding their animal health portfolios to include livestock vaccines, antiparasitics, antibiotics, nutritional supplements, and preventive healthcare products. This trend is improving product accessibility for livestock farmers, particularly in rural and semi-urban areas.

North America Livestock Therapeutics & Vaccines Market

North America held the largest market share of 40% in 2025 in the livestock therapeutics & vaccines industry, and it is anticipated to expand at a 5.3% CAGR over the forecast period.

• The North America market is characterized by the presence of a highly developed animal health ecosystem, large-scale commercial livestock operations, and strong regulatory support for disease prevention and control. The region is home to leading animal health companies such as Zoetis, Merck Animal Health, Elanco Animal Health, and Boehringer Ingelheim, which continue to invest in innovative vaccines, biologics, and long-acting therapeutics.
• Furthermore, increasing emphasis on biosecurity, antimicrobial stewardship, livestock disease surveillance, and precision livestock farming is accelerating the adoption of advanced veterinary healthcare products. Rising government support for animal disease monitoring and expanding investments in veterinary research and development are expected to further strengthen market growth across the region throughout the forecast period.

The U.S. livestock therapeutics & vaccines market size reached USD 6.6 billion in 2025, growing from USD 6.2 billion in 2024.  

• The U.S. dominated the North America livestock therapeutics & vaccines industry in 2025 owing to its large commercial cattle, poultry, and swine industries, robust veterinary healthcare infrastructure, and continuous investment in animal disease prevention.
• According to the United States Department of Agriculture, the U.S. cattle and calves inventory totaled 86.7 million head as of January 1, 2025, highlighting the substantial demand for veterinary therapeutics, vaccines, reproductive health products, and antiparasitics treatments. In addition, the country maintains one of the world's largest poultry industries, driving routine vaccination against diseases such as Newcastle disease and highly pathogenic avian influenza.
• Major companies continue to expand their product portfolios through innovation in vaccines, long-acting injectables, monoclonal antibodies, and precision livestock health solutions. Government-led disease surveillance and biosecurity programs further strengthen market growth.

Europe Livestock Therapeutics & Vaccines Market

Europe market accounted for USD 4.8 billion in 2025 and is anticipated to show considerable growth over the forecast period.

• The Europe livestock therapeutics & vaccines industry is driven by stringent animal health regulations, widespread adoption of preventive veterinary medicine, and a well-established livestock production industry. The region benefits from comprehensive disease surveillance programs and strong government initiatives aimed at improving animal welfare and reducing the spread of transboundary animal diseases.
• According to Eurostat, the European Union had 132 million pigs, 72 million bovine animals, and 67 million sheep and goats in 2024, creating sustained demand for vaccines, anti-infectives, antiparasitics, and reproductive health products.
• Major companies in the region continue to expand their veterinary portfolios through biologics, next-generation vaccines, and precision animal health technologies. Furthermore, increasing focus on antimicrobial stewardship and sustainable livestock production is expected to support continued market growth.  

The Germany livestock therapeutics & vaccines market is experiencing robust growth in Europe market.

• The Germany market is driven by the country's advanced veterinary healthcare infrastructure, strong livestock industry, and stringent animal health and welfare regulations. Germany continues to emphasize preventive disease management through routine vaccination, biosecurity measures, and continuous disease surveillance across cattle, swine, and poultry farms.
• According to Destatis, Germany had approximately 10.5 million cattle and 21.5 million pigs in 2024, creating sustained demand for veterinary vaccines, anti-infectives, antiparasitics, and reproductive health products. Furthermore, increasing investments in precision livestock farming, antimicrobial stewardship initiatives, and digital herd health management are expected to support long-term market growth.

Asia Pacific Livestock Therapeutics & Vaccines Market

The Asia Pacific market witnessed substantial growth of 6.1% during the analysis period.

• The Asia Pacific livestock therapeutics & vaccines industry is witnessing robust growth owing to the rapid expansion of commercial livestock farming, increasing consumption of animal-derived protein, and rising awareness regarding animal disease prevention.
• Countries such as China, India, Japan, Australia, and Vietnam are investing in veterinary infrastructure, vaccination campaigns, and livestock productivity improvement programs to strengthen food security. The region has experienced repeated outbreaks of diseases and greater adoption of vaccines, diagnostics, and biosecurity measures.
• In addition, expanding dairy, poultry, aquaculture, and swine industries, coupled with increasing government support for disease surveillance and livestock modernization, are creating substantial opportunities for manufacturers of veterinary biologics and advanced livestock healthcare products throughout the forecast period.

China livestock therapeutics & vaccines market is poised to witness high growth over the analysis period.  

• The China livestock therapeutics & vaccines industry is driven by the country's large livestock population, expanding commercial animal farming, and increasing investments in animal disease prevention and food security.
• China has strengthened vaccination programs and biosecurity measures following outbreaks of African swine fever and highly pathogenic avian influenza, resulting in greater adoption of veterinary vaccines and therapeutics.
• According to the National Bureau of Statistics of China, China produced approximately 96.63 million tonnes of meat in 2024, reflecting the scale of its livestock industry and the need for effective animal healthcare solutions.
• Furthermore, increasing investments in veterinary biologics, precision livestock farming, and disease surveillance, along with growing demand for high-quality animal protein, are expected to support continued market growth over the forecast period.  

Latin America Livestock Therapeutics & Vaccines Market

The Brazil livestock therapeutics & vaccines industry is witnessing substantial growth in Latin America.  

• The Brazil market is driven by the country's position as one of the world's largest producers and exporters of beef, poultry, and pork, creating substantial demand for disease prevention and livestock health management solutions. Increasing commercial livestock farming, expanding veterinary healthcare services, and government initiatives to control transboundary animal diseases continue to support market growth.
• According to Instituto Brasileiro de Geografia e Estatística, Brazil's cattle herd reached approximately 238.6 million head in 2024, the largest on record, reinforcing the need for vaccines, antiparasitics, anti-infectives, and reproductive health products.
• In addition, vaccination and surveillance programs targeting diseases such as foot-and-mouth disease and brucellosis are improving herd health across the country. Further, increasing exports of animal protein, investments in precision livestock farming, and growing adoption of veterinary biologics are expected to drive continued market expansion over the forecast period.

Middle East and Africa Livestock Therapeutics & Vaccines Market

The Saudi Arabia livestock therapeutics & vaccines industry is witnessing substantial growth in Middle East and Africa.  

• The Saudi Arabia market is experiencing steady growth, supported by increasing investments in livestock development, national food security initiatives, and expanding veterinary healthcare services. The country is strengthening disease prevention programs and biosecurity measures to improve the productivity of cattle, sheep, goats, camels, and poultry.
• According to General Authority for Statistics, Saudi Arabia's livestock population exceeded 22 million head in 2023, with sheep and goats accounting for the majority of the herd. This large animal population continues to drive demand for vaccines, antiparasitics, anti-infectives, and reproductive health products.
• Furthermore, government programs under Saudi Vision 2030 are encouraging modernization of the livestock sector through improved veterinary infrastructure, disease surveillance, and advanced farm management practices. Rising domestic meat and dairy production, coupled with growing adoption of preventive veterinary medicine, is expected to support sustained market growth over the forecast period.

Livestock Therapeutics & Vaccines Market Share 

The top 5 companies in the market account for approximately 59.5% of the market share, including Zoetis, Merck Animal Health, Elanco Animal Health, Boehringer Ingelheim, and Ceva Santé Animale. These leading animal health companies focus on developing innovative veterinary therapeutics and vaccines. Their research and development pipelines emphasize recombinant vaccines, long-acting injectable formulations, and novel vaccine platforms to address emerging infectious and transboundary animal diseases across cattle, swine, poultry, sheep, and aquaculture.

Additionally, players such as Virbac, Vetoquinol, and Phibro Animal Health are intensifying competition by expanding their veterinary pharmaceutical portfolios and introducing next-generation biologics and livestock vaccines. Companies are increasingly engaging in strategic partnerships, mergers and acquisitions, manufacturing expansions, and investments in precision animal health technologies to strengthen their market presence, enhance global distribution networks, and accelerate the commercialization of innovative livestock therapeutics and vaccines, thereby driving sustained market growth.

Livestock Therapeutics & Vaccines Market Companies

Major players operating in the livestock therapeutics & vaccines industry are:

• Zoetis
• Merck Animal Health (MSD Animal Health)
• Boehringer Ingelheim Animal Health
• Elanco Animal Health
• Ceva Santé Animale
• Virbac
• HIPRA
• Vetoquinol
• Phibro Animal Health
• Indian Immunologicals
• Vaxxinova
• Biogénesis Bagó
• Bioveta
• Neogen Corporation
• Norbrook

Zoetis

Zoetis is the global player in animal health with a broad portfolio of vaccines, anti-infectives, parasiticides, and diagnostics for livestock. The company is recognized for continuous innovation and integrated herd health solutions. Its flagship products include Draxxin (tulathromycin) for bovine respiratory disease and Poulvac vaccines for poultry disease prevention.

Merck Animal Health

Merck Animal Health offers a comprehensive range of livestock vaccines, pharmaceuticals, and digital monitoring technologies. The company's strength lies in combining therapeutics with precision livestock management solutions. Key products include Bovilis vaccines for cattle and Porcilis vaccines for swine disease prevention and herd health improvement.

Elanco Animal Health

Elanco specializes in livestock productivity, disease prevention, and food safety through an extensive portfolio of vaccines, parasiticides, anti-infectives, and nutritional products. The company focuses on sustainable animal production. Its well-known products include Experior for beef cattle and Pulmotil (tilmicosin) for respiratory disease management.

Boehringer Ingelheim

Boehringer Ingelheim is recognized for its strong expertise in veterinary vaccines and biologics, particularly for cattle, swine, and poultry. The company emphasizes preventive healthcare and innovation in infectious disease control. Its flagship products include Ingelvac CircoFLEX for swine circovirus and VAXXITEK HVT+IBD vaccine for poultry.

Livestock Therapeutics & Vaccines Industry News

• In January 2025, Ceva Sante Animale and Touchlight signed an agreement to use dbDNA technology to develop and manufacture products across the animal health sector. Through this, the company strengthens its product portfolio and leverages advanced technologies.
• In January 2025, Vaxxinova received USDA approval for its VAXXON SHS, a live avian metapneumovirus vaccine import in the U.S. This vaccine was used to protect against Swollen Head Syndrome in poultry. The first ever approval for the import of live vaccines in the U.S. marked a significant milestone in the fight against avian metapneumovirus (aMPV).
• In February 2025, Elanco partnered with Medgene, enabling it to utilize Medgene’s innovative platform technology. Through this agreement, Medgene will commercialize the vaccine intended to be used for highly pathogenic avian influenza (HPAI) in dairy cattle. The expansion was focused on improving the range of preventive measures undertaken to combat disease.
• In September 2024, Boehringer Ingelheim acquired Saiba Animal Health, focused on the development of drugs for pets to manage chronic diseases. This strategic acquisition helped the company to broaden its product portfolio and strengthen its animal health R&D pipeline.
• In September 2024, Elanco Animal Health announced the approval of Zenrelia for controlling pruritus (itching) associated with allergic dermatitis and atopic dermatitis in dogs. This launch facilitated the company boosting revenue growth by adding a new product.
• In June 2024, Merck Animal Health received approval for NOBIVAC NXT Canine Flu H3N2 by the USDA, which is the first and only RNA-particle technology vaccine for treating dogs with influenza. This product’s approval has helped the company broaden its offerings and enhance its position in the market.

The livestock therapeutics & vaccines market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Therapeutics
  • Antibiotics/anti-infectives
  • Antiparasitics agents
  • Anti-inflammatory agents
  • Corticosteroids
  • Tranquilizers
  • Cardiovascular drugs
  • Gastrointestinal drugs
  • Other therapeutics
• Vaccines
  • Live attenuated vaccines
  • Inactivated vaccines
  • Recombinant & subunit vaccines
  • Toxoid vaccines
  • Other vaccines

Market, By Animal Type

• Poultry
• Cattle
• Swine
• Sheep and goats
• Aquaculture
• Other animal types

Market, By Disease Indication

• Bacterial diseases
• Viral diseases
• Parasitic diseases
• Fungal diseases
• Other disease indications

Market, By Route of Administration

• Injectable (parenteral)
• Oral
• Topical
• Intranasal/inhalation
• Other route of administration

Market, By Distribution Channel

• Veterinary hospital pharmacies
• E-commerce
• Retail pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE